Recent Study: Belgium Pharmaceuticals & Healthcare Report Q4 2014

Multinational firms find Belgium to be an attractive investment destination as a European hub for clinical trials, new drug development and niche research. Even though per capita spending on pharmaceuticals is relatively high, it is subjected to continual downward pressure from Eastern Europe and Asia, which translates into growth opportunities for generic drugs. However, prescribers' brand loyalty, pay-to-delay deals, the near-universal unpopularity of commodity generics and a lack of perfect competition in the pharmaceutical sector constitute key impediments to further generic expansion.

Headline Expenditure Projections

* Pharmaceuticals: EUR5.83bn (USD7.70bn) in 2013 to EUR5.79bn (USD7.76bn) in 2014; -0.62% in local currency terms and 0.9% in US dollar terms. Local currency forecast lower than in Q 3 14.
* Healthcare: EUR41.79bn (USD55.17bn) in 2013 to EUR42.76bn (USD57.29bn) in 2014; +2.3% in local currency terms and 3.8% in US dollar terms. Local currency forecast in line with Q 3 14.

Full Report Details at
- http://www.fastmr.com/prod/878937_belgium_pharmaceuticals_healthcare_report_q4_2014.aspx?afid=301

Risk/Reward Rating:

In our Q414 Pharmaceutical Risk/Reward Ratings Belgium still ranks sixth out of the fifteen markets surveyed in the Western European region. It posted above or average scores in all indicators, with the exception of Country Risks.

Key Trends And Developments

* In August 2014, UCB announced that it has joined the Multi-Sponsor Environment which allows the responsible sharing of clinical study data as a way to uncover new scientific knowledge or insights, advance medicine and ultimately benefit patients and other stakeholders. In line with its vision for patient-centered leadership, UCB is the first midcap biopharma company to join this new environment. The environment allows researchers to request access to anonymised patient level data and supporting documents from clinical studies to conduct further research. UCB's policy on data sharing embraces the Principles for Responsible Clinical Trial Data Sharing released by the US and...

The Belgium Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Belgium Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Belgian pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Belgium to test other views - a key input for successful budgeting and strategic business planning in the Belgian pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q4 2014
- Sweden Pharmaceuticals & Healthcare Report Q4 2014
- Kenya Pharmaceuticals & Healthcare Report Q4 2014
- Argentina Pharmaceuticals & Healthcare Report Q4 2014
- Peru Pharmaceuticals & Healthcare Report Q4 2014